LHDX Insider Trading Activity and SEC Form 4 Filings
LHDX insider trading summary
No open-market insider purchases or sales of Lucira Health, Inc. (LHDX) have been reported on SEC Form 4 in the past 12 months.
Latest LHDX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 7, 2023 | Kevin Walter Collins | Chief Revenue Officer | Sell | $39K (81,717 @ $0.48) |
| Mar 7, 2023 | Richard Clavano Narido | Chief Financial Officer | Sell | $1K (2,382 @ $0.45) |
| Mar 6, 2023 | Richard Clavano Narido | Chief Financial Officer | Sell | $1K (1,910 @ $0.57) |
| Mar 3, 2023 | Erik T. Engelson | President and Chief Executive | Sell | $592K (574,666 @ $1.03) |
| Mar 3, 2023 | Richard Clavano Narido | Chief Financial Officer | Sell | $12K (10,674 @ $1.14) |
| Mar 3, 2023 | Richard Clavano Narido | Chief Financial Officer | Sell | $5K (4,742 @ $1.00) |
| Mar 3, 2023 | Kevin Walter Collins | Chief Revenue Officer | Sell | $35K (30,102 @ $1.15) |
| Mar 3, 2023 | Richard Clavano Narido | Chief Financial Officer | Sell | $10K (9,675 @ $1.07) |
| Mar 3, 2023 | Anthony Joseph Allen | Chief Operations Officer | Sell | $8K (8,405 @ $1.00) |
| Mar 3, 2023 | Erik T. Engelson | President and Chief Executive | Sell | $65K (60,000 @ $1.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.